Drug intelligence / Profile preview

KF-0210

Development stage: Phase 1
Lead developer: Keythera Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

KF-0210 is a small molecule oral drug developed by Keythera Pharmaceuticals. It acts as a highly selective and potent antagonist of the E-type prostaglandin receptor, specifically the EP4 receptor. KF-0210 is being investigated for its potential in treating various cancers, including advanced solid tumors, non-small cell lung cancer, colorectal cancer, and others.

Other names: KF 0210KF0210KF-0210

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)

Beyond the preview

Go deeper on KF-0210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KF-0210.

Explore the full profile